• Journal of the Korean Operations Research and Management Science Society
• /
• v.1 no.1
• /
• pp.11-13
• /
• 1976

• The Korean Nurse
• /
• v.24 no.3 s.131
• /
• pp.29-35
• /
• 1985

• KOMUNHWA
• /
• no.35
• /
• pp.95-101
• /
• 1989

• 대한근관절건강학회:학술대회논문집
• /
• 2001.04a
• /
• pp.167-172
• /
• 2001

• Journal of the korean veterinary medical association
• /
• v.14 no.1
• /
• pp.15-17
• /
• 1978

• Clinical and Experimental Pediatrics
• /
• v.45 no.5
• /
• pp.568-574
• /
• 2002

• Proceedings of the PSK Conference
• /
• 2002.04a
• /
• pp.71-73
• /
• 2002

• Proceedings of the Culinary Society of Korean Academy Conference
• /
• 2005.10a
• /
• pp.89-97
• /
• 2005

• Journal of Ginseng Research
• /
• v.22 no.3
• /
• pp.216-221
• /
• 1998

We examined the anti-invasive activity of ginsenosides Rhl, Rha on the highly metastatic HT1080 human fibrosarcoma cell line. In vitro invasion assay showed ginsenoside Rhr reduced tumor cell invasion through a reconstituted basement membrane in a transwell chamber more than ginsenoside Rh1. Significant down-regulation of matrix metalloproteinase-9 (MMP-9) by ginsenosides Rh, and Rh2 was detected by Northern blot analysis. However, the expression of MMP-2 was not affected by Rh, and Rhr. The expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) was increased by Rhl after 0.5, 1 or 3 day-treatment but reduced after 6 day-treatment. However, the expression of TIMP-2 was not changed by treatment with Rh2. Plasminogen activator inhibitor (PAI) and urokinase-type plasmlnogen activator (uPA) were not changed by treatment with Rh1 and Rh2 for 3 and 6 days. Quantitative gelatin-based zymography confirmed a markedly reduced expression of MMP-9 but MMP-2 after treatments with ginsenosides Rhl and Rha. These results suggest that down-regulation of MMP-9 contributes to the anti-invasive activity of ginsenosides Rhl and Rhr in the HT1080 cells.

• Asian Pacific Journal of Cancer Prevention
• /
• v.15 no.5
• /
• pp.2185-2190
• /
• 2014

Chemotherapy has significantly improved the prognosis of cancer patients with various malignancies. However, female patients, especially those whoich are premenopausal, suffer from significant chemotherapy induced ovarian function impairment, which decreases their quality of life. Many new techniques for ovarian preservation have been established in recent years. Although the use of gonadotrophin releasing hormone analogues (GnRHa) for this purpose is not a new concept, its effectiveness in protection of ovarian function is still debatable. This article deals with studies and metaanalyses which have been undertaken in the past, demonstrating the impact of GnRHa in ovarian function preservation, and whether their use can be implemented in routine practice.